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Background: There is now abundant evidence that inhibition of steroid
sulphatase alone or in conjunction with inhibition of aromatase may enhance the
response of postmenopausal patients with hormone-dependent breast cancer to
this type of endocrine therapy. Additionally, sulphatase inhibition has been
proposed to be of potential therapeutic bene¢t in the immune system and for
neuro-degenerative diseases. After the ¢nding that our ¢rst highly potent active
site-directed steroid sulphatase inhibitor, oestrone-3-O-sulphamate (EMATE), was
highly oestrogenic, we proposed non-steroidal coumarin sulphamates such as
4-methylcoumarin-7-O-sulphamate (COUMATE) as alternative non-steroidal
steroid sulphatase inhibitors. In this work, we describe how tricyclic coumarin-
based sulphamates have been developed which are even more potent than
COUMATE, are non-oestrogenic and orally active. We also discuss potential
mechanisms of action.
Results: 4-Ethyl- (4), 4-(n-propyl)- (6), 3-ethyl-4-methyl- (8), 4-methyl-3-
(n-propyl)coumarin-7-O-sulphamate (11); the tricyclic derivatives 665COUMATE
(13), 666COUMATE (15), 667COUMATE (17), 668COUMATE (20) and the
tricyclic oxepin sulphamate (22) were synthesised. In a placental microsome
preparation, all of these analogues were found to be more active than COUMATE
in the inhibition of oestrone sulphatase, with the most potent inhibitor being
667COUMATE which has an IC50 of 8 nM, some 3-fold lower than that for
EMATE (25 nM). In addition, 667COUMATE was also found to inhibit DHEA-
sulphatase some 25-fold more potently than EMATE in a placental microsome
preparation. Like EMATE, 667COUMATE acts in a time- and concentration-
dependent manner, suggesting that it is an active site-directed inhibitor. However,
in contrast to EMATE, 667COUMATE has the important advantage of not being
oestrogenic. In addition, we propose several diverse mechanisms of action for
this active site-directed steroid sulphatase inhibitor in the light of recent
publications on the crystal structures of human arylsulphatases A and B and the
catalytic site topology for the hydrolysis of a sulphate ester.
Conclusions: A highly potent non-steroidal, non-oestrogenic and irreversible
steroid sulphatase inhibitor has been developed. Several mechanisms of action
for an active site-directed steroid sulphatase inhibitor are proposed. With
667COUMATE now in pre-clinical development for clinical trial, this should allow
the biological and/or clinical signi¢cance of steroid sulphatase inhibitors in the
treatment of postmenopausal women with hormone-dependent breast cancer and
other therapeutic indications to be fully evaluated.
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Introduction
In postmenopausal women with breast cancer, about one-
third of patients have hormone-dependent tumours, the
growth and development of which require the stimulation
of oestrogens. Studies have shown that endocrine therapy
plays an important role in the treatment of this type of
breast cancer and that hormonal manipulation, through
the inhibition of enzymes within the steroid biosynthetic
cascade, may be one route to controlling the disease.
The aromatase enzyme, which converts androstenedione to
oestrone (Figure 1), has been the prime target for reducing
oestrogen levels. Several potent, well-tolerated and highly
selective aromatase inhibitors are currently in clinical use.
However, the clinical response of treated patients to the
latest generation of aromatase inhibitors has been disap-
pointing and this has cast doubt on the ef¢cacy of treating
hormone-dependent breast cancer (HDBC) by aromatase
inhibitors alone without inhibiting concurrently the activ-
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ities of other enzymes involved in the production of oes-
trogenic steroids [1,2]. There is now abundant evidence to
suggest that the hydrolysis of oestrone sulphate (E1S, Fig-
ure 1) to oestrone (E1, Figure 1) by oestrone sulphatase
(E1-STS) is the main source of oestrogens to tumours [3^
9]. In addition, the production of androstenediol (Adiol),
and to a lesser extent oestradiol (E2), via dehydroepian-
drosterone (DHEA) (Figure 1) could also signi¢cantly con-
tribute to the oestrogenic stimulation of hormone-depen-
dent breast tumours [10^13]. Adiol, an androgen which
binds to oestrogen receptor and has oestrogenic properties,
originates from DHEA sulphate (DHEA-S) once it has
been hydrolysed to DHEA (Figure 1) by DHEA sulpha-
tase (DHEA-STS) [12^16]. Therefore, steroid sulphatase
inhibitors, when used alone or in concert with an aromatase
inhibitor, may enhance the response of hormone-depen-
dent breast tumours to this type of endocrine therapy by
reducing not only the formation of E1 from E1S but also
the synthesis of other oestrogenic steroids such as Adiol via
DHEA from DHEA-S.
In addition to its oncological role there is now evidence to
suggest that steroid sulphatase may regulate part of the
immune response [17,18]. In an animal model, it has
been shown that inhibition of steroid sulphatase can mod-
ulate the immune response and have a bene¢cial effect in
collagen-induced rheumatoid arthritis [19]. Recent studies
have also suggested that inhibition of steroid sulphatase
can potentiate the memory enhancing properties of
DHEA-S [20^22].
Oestrone-3-O-sulphamate (EMATE, Figure 2) was our ¢rst
highly potent steroid sulphatase inhibitor which exhibits
active site-directed inhibition against E1-STS and
DHEA-STS, both in vitro, and in vivo when administered
orally or subcutaneously [23^28]. However, despite its po-
tent biological activities, it is now unlikely that EMATE
will be developed for clinical trials in the treatment of
HDBC. A recent study has demonstrated that EMATE
and its congener, oestradiol-3-O-sulphamate, are more
oestrogenic than ethinyloestradiol when administered or-
ally in the rat [29]. Although the mechanism for this oes-
trogenicity has not been fully elucidated, this undesirable
property of EMATE strongly reinforced the preference for
administering endocrine therapy via non-steroidal agents,
which may not themselves, or through their metabolites,
exert unwanted and/or unpredictable endocrinological ef-
fects.
We have now established that non-steroidal coumarin sul-
phamates such as coumarin-7-O-sulphamate (1, Figure 2)
and 4-methylcoumarin-7-O-sulphamate (COUMATE, Fig-
ure 2) are steroid sulphatase inhibitors [28,30]. Although
the orally active COUMATE is less potent than EMATE
as an active site-directed inhibitor, it has the crucial advan-
tage of being non-oestrogenic [31]. We have recently studied
structure^activity relationships for COUMATE which
have shown, inter alia, that the coumarin ring system of
COUMATE is pivotal for its inhibitory activities [28]. In
addition, one analogue of COUMATE, 3,4-dimethyl-
coumarin-7-O-sulphamate (2, Figure 2), was found to be
some 12-fold more potent than COUMATE as an E1-
STS inhibitor in intact MCF-7 breast cancer cells (IC50 =
30 nM) [28].
It is possible that the higher potency of 2 observed in
comparison with 1 and COUMATE might be attributed
to its stronger binding to the enzyme active site via a
hydrophobic interaction provided by the methyl groups
at the 3- and 4-positions. Since coumarin sulphamates
such as 2 are presumably A/B ring mimics of EMATE, it
is predicted that analogues with substituents of increased
hydrophobicity at the 3- and/or 4-positions might be more
potent steroid sulphatase inhibitors. Previous studies in
this ¢eld have already highlighted an association between
the hydrophobicity of a steroid sulphatase inhibitor and its
inhibitory activity. Hence, the potency of non-steroidal,
single-aryl ring steroid sulphatase inhibitors such as p-al-
kylphenyl phosphates [32] and (p-O-sulphamoyl)-N-alkano-
yl tyramines [33,34] has been shown to increase as the
length of the alkyl group increases. Recently, such associ-
ation has also been demonstrated in steroid sulphatase
inhibitors which are derivatives of E2. Compounds such
as 17L-(N-alkylcarbamoyl)oestradiol-3-O-sulphamates [35],
17L-(N-alkanoyl)oestradiol-3-O-sulphamates [35] and 17K-
benzyl derivatives of oestradiol-3-O-sulphamate [36] have
been found to be potent. To explore any association be-
tween potency and hydrophobicity in two-ring compounds
such as coumarin sulphamates, and also as part of our on-
going programme to develop an alternative non-steroidal
and non-oestrogenic candidate to EMATE for clinical trials,
we report here (i) the replacement of the methyl group of
COUMATE at the C4-position, and that of 2 at the C3-
position with an ethyl and n-propyl group; and in particular
also (ii) the synthesis of several novel tricyclic derivatives
of coumarin sulphamates. Hence, 4-ethylcoumarin-7-O-sul-
phamate (4, Scheme 1), 4-(n-propyl)coumarin-7-O-sulpha-
mate (6), 3-ethyl-4-methylcoumarin-7-O-sulphamate (8), 4-
methyl-3-(n-propyl)coumarin-7-O-sulphamate (11); the tri-
cyclic derivatives 665COUMATE (13, Scheme 2; for the
chemical name see Materials and methods), 666COU-
MATE (15), 667COUMATE (17), 668COUMATE (20)
and the tricyclic oxepin sulphamate (22) were synthesised
and examined for inhibitory activities against E1-STS in
vitro.
Some efforts have been made recently to understand the
mechanism of action of steroid sulphatase and how some
inhibitors of this enzyme might work [25,28,32,37^39]. In
the light of recent publications on the crystal structures of
human arylsulphatase A and arylsulphatase B and the cata-
lytic site topology for the hydrolysis of sulphate group [40^
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43], we also reappraise here our previously proposed mech-
anism of action for an active site-directed steroid sulpha-
tase inhibitor [28,37,38].
Results and discussion
Since the unexpected discovery that the potent steroid
sulphatase inhibitor EMATE is also a highly active oestro-
gen, we have been exploring alternative phenolic-based
non-steroidal ring structures whose sulphamates might ex-
hibit steroid sulphatase inhibition but be devoid of oestro-
genicity. Our interest in the coumarin ring system
stemmed from the reported oestrogenicity of coumestrol
(23, Figure 3), a plant derived tetracyclic coumaric com-
pound [44,45]. Structurally, this phytooestrogen noticeably
bears a resemblance to the oestrogens because of an ap-
parently crude mimicry of the steroid skeleton. Therefore,
the coumarin moiety of the molecule might be a mimic of
the A/B ring of oestrogens. We then reasoned that sulpha-
mates of simple bicyclic coumarins might exhibit steroid
sulphatase inhibition but they themselves or their starting
coumarins are unlikely to be oestrogenic. Indeed, this rea-
soning was corroborated with COUMATE (Figure 2),
which was found to be an effective, orally active, non-oes-
trogenic active site-directed E1-STS inhibitor [28,30,31];
and also subsequently with its 3-methyl derivative, 3,4-di-
methylcoumarin-7-O-sulphamate (2, Figure 2) [28].
The parent coumarins for this study were prepared by
Pechmann reaction between resorcinol and the correspond-
ing L-ketoester (Schemes 1A and 2A) in the presence of an
Figure 1. The origin of oestrogenic steroids in postmenopausal women: AR, aromatase; ST, sulphotransferase; STS, sulphatase; 17L-HSD,
17L-hydroxysteroid dehydrogenase; 3L-HSD-isomerase, 3L-hydroxysteroid dehydrogenase v5,v4-isomerase; ER, oestrogen receptor.
Figure 2. Structures of EMATE, coumarin-
7-O-sulphamate (1), COUMATE and 3,4-
dimethylcoumarin-7-O-sulphamate (2).
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equimolar mixture of tri£uoroacetic acid and concentrated
sulphuric acid [46] as the condensing agent. For those
coumarins which had been reported in the literature, our
modi¢ed method has produced comparable yields. Since
many of these parent coumarins were characterised almost
50 years ago, we now report their hitherto unavailable
spectroscopic data.
It is interesting to note that, in contrast to lower members
of the series whose yields are s 60%, the tricyclic coumar-
in 19 (Scheme 2A) was only isolated in around 25^33%
yield (two attempts) with a recovery of almost half of the
methyl 2-oxocyclooctane carboxylate used initially for the
reaction. When the higher 6613COUMARIN (24, Figure
3) was prepared from the corresponding 13-membered cy-
clic L-ketoester in a similar manner, the crystalline product
was isolated in 58% yield (data not shown). Although the
mechanism for the relatively poor yield of 19 has not been
fully elucidated, we suspect that the ring size of its starting
8-membered cyclic L-ketoester could be a contributory fac-
tor. It has been shown that when the carbonyl carbon of a
5-, 6-, 7-, 8- or 13-membered cyclanone becomes sp3(C^
OH) hybridised, the highest I-strain is observed in the
resulting saturated cyclic molecule of cyclooctanone
[47,48]. Since an equivalent sp2Csp3 conversion at the
carbonyl carbon of the L-ketoester is also involved upon
the penultimate Friedel^Crafts cyclisation step of the
Pechmann reaction, it is anticipated that the formation of
19 is the most disfavoured, accounting for its poorest yield
in our series of tricyclic coumarins.
The inhibitory activities of the 3-alkyl-4-methyl- and 4-
alkylcoumarin sulphamates against E1-STS activity in pla-
cental microsomes are shown in Table 1. For the purpose
of comparison, the inhibitory activities of 1, COUMATE
and 2 obtained from our previous work [28] are also in-
cluded. It is clear that all these derivatives (4, 6, 8 and 11)
were found to be more potent E1-STS inhibitors than
COUMATE. The substitution at the 3-position of the cou-
marin ring with alkyl groups of longer chain length proved
to be more productive than that at the 4-position as shown
by the overall higher potencies of the inhibitors in the
former series. Although the methyl group at C4 of the
inhibitors in the 3-alkyl series must also be a contributory
factor to the higher potency observed, it is apparent that
the hydrophobic interactions between the amino acids in
the active site, which naturally recognise the steroid scaf-
fold, and the alkyl substituents are more effective when
these substituents are placed at the C3 position of the
coumarin ring. Since we have proposed that coumarin sul-
phamates are steroid sulphatase inhibitors by virtue of their
structural mimicry of the A/B ring of EMATE, it is con-
ceivable that the positioning of alkyl substituents with high
rotational degrees of freedom at the 4-position of the cou-
marin ring may be counterproductive. The active site of
steroid sulphatase, like many other enzymes with a steroid
Scheme 1. (A) Structures and synthesis of coumarins (3, 5, 7 and 10) and their corresponding sulphamates (4, 6, 8 and 11).
(B) Synthesis of ethyl (2-n-propyl)acetoacetate (9). (i) CF3COOH/conc. H2SO4 (1:1), 0³CCr.t.; (ii) NaH/DMF, H2NSO2Cl; (iii) K2CO3/
(Bu)4NCl3WxH2O/H2O/CHCl3, r.t.
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as substrate, is expected to have limited accommodation
for substituents at the C1/C11/C12 edge of the steroid
scaffold. For this reason, the relatively weaker inhibitions
shown by the inhibitors in the 4-alkyl series can be attrib-
uted to their less favourable binding to the enzyme active
site.
Our prediction that coumarin sulphamate analogues with
substituents of increased hydrophobicity at the 3- and/or 4-
positions should be more potent steroid sulphatase inhib-
itors has been further con¢rmed by the even higher po-
tency observed in most of the tricyclic coumarin sulpha-
mates, e.g. both 17 and 20 gave almost complete inhibition
at 1 WM in a placental microsome preparation (Table 2).
The best inhibitor in this series is 17 (667COUMATE)
whose IC50 value for the inhibition of E1-STS activity in
placental microsomes is 8 nM (Figure 4A) which is some
three-fold more potent than EMATE in the same assay
(IC50 = 25 nM) (Figure 4A). Like EMATE, but much
more effectively, 17 also inhibited the hydrolysis of
DHEA-S by DHEA-STS in a placental microsome prepa-
ration (Figure 4B) with an IC50 of 4.5 nM (cf. 110 nM for
EMATE [25]).
The time- and concentration-dependent inactivation of the
E1-STS activity in placental microsomes by 17 is shown in
Figure 5A. As with EMATE, the inhibition by 17 is bipha-
sic, indicating that the inhibitor shares a similar mechanism
of action to that proposed for EMATE, which we have
postulated acts via irreversible sulphamoylation of one or
more residues in the enzyme active site [28]. The double-
reciprocal plot of the ¢rst-order rates of inactivation versus
the concentrations of 17 is shown in Figure 5B. The ap-
parent Ki for 17 was found to be 40 nM which is signi¢-
cantly lower than that for EMATE (670 nM) [25]. This
suggests that the lower IC50 value observed for 17 in com-
Scheme 2. (A) Structures and synthesis of tricyclic coumarins (12, 14, 16 and 19) and their corresponding sulphamates (13, 15, 17 and
20). (B) Sulphation of coumarin 16. (C) Synthesis of the tricyclic oxepin (21) and its sulphamate (22). (i) CF3COOH/conc. H2SO4 (1:1),
0³CCr.t.; (ii) NaH/DMF, H2NSO2Cl; (iii) Me3NWSO3, 1 M NaOH (aq).
Figure 3. Structures of coumestrol (23) and 6613COUMARIN
(24).
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parison with EMATE could be attributed to a higher af-
¢nity of 17 for the enzyme active site. As calculated by the
method of Kitz and Wilson [49], the overall rate constant
for the decrease in activity was found to be 3.45U1033 s31
for 17. To date, the only successful approach to the design
of steroid sulphatase inhibitors which are more potent than
EMATE, the benchmark inhibitor of this ¢eld, has been
by incorporating hydrophobic substituents at the C17 posi-
tion of EMATE [35,36]. Although a series of (p-sulphamo-
yl)-N-alkanoyl tyramines have also shown good inhibitory
activities, the best compound in this series (N-tetradecano-
yl) has been reported to be less potent than EMATE [35].
We demonstrate here, therefore, for the ¢rst time that
superior inhibition over EMATE can be achieved with
an inhibitor that is essentially non-steroidal by nature.
Although the coumarin moiety of 17 is expected to mimic
the A/B ring of EMATE, its third ring could not be de-
scribed as a close mimic of the C/D ring of EMATE when
its preferred conformation is examined. Our molecular
modelling of 17 (Graphics 1) shows that its 7-membered
ring is largely in the chair form, which is similar to that of
cycloheptene [50], with the CNC moiety taking the place
of one of the ring carbon atoms in the cyclohexane chair.
Despite this lack of absolute conformational resemblance
of 17 to EMATE, particularly in the C/D ring regions, the
hydrophobic interactions between its cycloalkene system
and neighbouring amino acid residues in the enzyme ac-
tive site must be effective and favourable. As a conse-
quence, the active site sulphamoylation, and hence inacti-
vation, of E1-STS by 17 must be facilitated. For 20,
despite a higher hydrophobicity by virtue of an extra meth-
ylene group, its lower potency than 17 observed could be
attributed to the highly strained multi-conformational cy-
clooctene system. It is possible that the binding conforma-
tion of the cyclooctene system of 20 might have less opti-
mal interactions with the amino acid residues of the
enzyme active site than the cycloheptene system of 17.
We have demonstrated previously that 7-(sulphooxy)-4-
methylcoumarin is a substrate for E1-STS [28]. However,
it is important to demonstrate the same with 667COU-
MARIN sulphate (18, Scheme 2B), which we synthesised
by treating a solution of 16 (Scheme 2) in sodium hydrox-
ide (V1 M) with sulphur trioxide-trimethylamine com-
plex. When 18 was incubated with placental microsomes
in the absence of EMATE (see Materials and methods),
only the free coumarin 16 was detected. However, hydro-
lysis of 18 by E1-STS was completely abolished by the
inclusion of EMATE in the reaction (data not shown).
These results therefore indicate that the tricyclic coumarin
sulphate 18 is a substrate for this enzyme.
The oestrogenic activity of 17 was also studied. Like
COUMATE [31], when administered orally, 17 was found
to be devoid of oestrogenicity as shown by its inability to
stimulate uterine growth in ovariectomised rats [78]. With
this lack of oestrogenicity, together with its higher active
site-directed inhibitory activity against E1-STS than
EMATE in vitro and also its ease of synthesis, 17 is now
Table 1
Inhibition of oestrone sulphatase activity in placental microsomes by 4-alkylcoumarin sulphamates (4 and 6) and 3-alkyl-4-methyl-
coumarin sulphamates (8 and 11) at various concentrations.
Compound % Inhibition þ S.D. of E1-STS activity in placental microsomes at various concentrations
0.1 WM 1 WM 10 WM
1 (C3-H, C4-H)a;b ^ ^ 78 þ 1
COUMATE (C3-H, C4-Me)b 6 10 63 þ 1 93 þ 1
2 (C3-Me, C4-Me)b 35 þ 1 88 þ 2 97 þ 4
4 (C3-H, C4-Et) 35 þ 1 88 þ 1 s 99
6 (C3-H, C4-n-propyl) 42 þ 2 94 þ 1 96 þ 1
8 (C3-Et, C4-Me) 57 þ 1 96 þ 1 s 99
11 (C3-n-propyl, C4-Me) 83 þ 1 97 þ 1 s 99
[3H]Oestrone sulphate (4U105 dpm), adjusted to 20 WM with unlabelled substrate, with or without the inhibitor at various concentrations,
was incubated with placental microsomes (125 Wg of protein/ml) for 30 min. The product formed was isolated by extraction into toluene
with [4-14C]oestrone (7U103 dpm) being used to monitor procedural losses. Each value represents the mean þ S.D. of triplicate measure-
ments.
as 90% at 50 WM.
bResults reproduced from [28].
Table 2
Inhibition of oestrone sulphatase activity in placental micro-
somes by tricyclic coumarin sulphamates (13, 15, 17 and 20)
and tricyclic oxepin sulphamate (22) at various concentra-
tions.
Compound % Inhibition þ S.D. of E1-STS
activity in placental microsomes at
various concentrations
0.01 WM 0.1 WM 1 WM
13 (665COUMATE)a 6 10 37 þ 1 91 þ 2
15 (666COUMATE)a 6 10 63 þ 1 93 þ 1
17 (667COUMATE) 48 þ 2 91 þ 1 s99
20 (668COUMATE) 17 þ 2 89 þ 1 s99
22 6 10 31 þ 5 94 þ 2
For details of the assay, refer to the legend of Table 1.
as 99% at 10 WM.
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Figure 4. (A) Dose^response curves for inhibition of oestrone sulphatase activity in placental microsomes by 667COUMATE (17, R) and
EMATE (a). Method as described for Table 1. (B) Dose^response curves for inhibition of DHEA-STS activity in placental microsomes by
667COUMATE (17). Method as described for Table 1 except [3H]DHEA-S (4U105 dpm) adjusted to 20 WM with unlabelled DHEA-S was
used.
Figure 5. (A) Time- and concentration-dependent inactivation of oestrone sulphatase by 667COUMATE (17). Placental microsomes (200
Wg of protein) were preincubated with the inhibitor at 0^0.5 WM for 0^10 min at 37³C followed by incubation with dextran^charcoal for 10
min at 4³C. Dextran^charcoal was sedimented by centrifugation, and portions of the supernatants were then incubated with [3H]oestrone
sulphate (20 WM) for 1 h at 37³C to assess remaining sulphatase activity. Duplicate experiments were run at each concentration, but
assays for residual activity were taken at different times in each experiment. (B) Double reciprocal plot of inactivation rate constant versus
667COUMATE concentration.
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in formal pre-clinical development for phase I clinical trial
for the treatment of postmenopausal women with HDBC.
In a limited structure^activity relationship study for our
tricyclic coumarin sulphamates, we enlarged the middle
ring of 666COUMATE (15, Scheme 2) from the K,L-un-
saturated N-lactonic to the unconjugated O-lactonic moiety
of 22 (Scheme 2). It is clear that the potency of 15 was
signi¢cantly reduced by such structural modi¢cation as
shown by the weaker inhibitory activity of 22 (Table 2).
This result is consistent with the ¢ndings from our recent
structure^activity relationships study on COUMATE
which have shown a similar detrimental effect to the po-
tency of the parent compound when the conjugation of the
coumarin ring is either disrupted or removed entirely [28].
Our explanation for this effect is that the breaking of the
S^O^Ar bond in the sulphamate group of coumarin sulpha-
mates such as COUMATE during sulphamoylation of E1-
STS is assisted by the extended conjugation present in the
coumarin motif. Such conjugation improves the leaving
group ability of coumarins by lowering the pKa of the phe-
nol (our recent ¢nding that the 4-nitro analogue of
EMATE is more potent than EMATE as a steroid sulpha-
tase inhibitor [51] has already suggested that the inhibitory
activity of an aryl sulphamate could be improved by en-
hancing the leaving group ability of the parent phenol, i.e.
lowering of pKa). Any disruption or removal of conjugation
in the ring system of coumarins, including that in 14,
should therefore render analogues with poorer leaving
group abilities (i.e. a higher pKa value for the parent phe-
nol) whose sulphamates are expected to be less active as
E1-STS inhibitors. However, the susceptibility of the un-
conjugated L,Q-unsaturated O-lactonic moiety of 22 to hy-
drolysis in phosphate buffered saline (pH = 7.4) used in the
bioassay could explain the relatively weak inhibition
shown by this inhibitor. It is possible that the tricyclic
structure of 22, supposedly required for good inhibitory
activity, is already lost prior to the binding of the inhibitor
to the enzyme active site.
Like other irreversible steroid sulphatase inhibitors re-
ported to date, 667COUMATE possesses a phenol sulpha-
mate ester which we have proposed to be the pharmaco-
phore for inhibitors acting mechanistically like EMATE
[28]. The mechanism(s) through which the sulphamate
group irreversibly inactivates steroid sulphatase have al-
ready been broadly proposed and discussed without the
knowledge of the enzyme active site (part of the dif¢culty
in obtaining the crystal structure of steroid sulphatase lies
in the crystallisation of this membrane-bound enzyme).
However, two recent publications on the crystal structures
of the soluble enzymes arylsulphatase A (ASA) [42]
and arylsulphatase B (ASB) [40], and related articles
[41,43,52,53] have provided valuable new insights into
the conserved active site of sulphatases in general and on
how a sulphatase enzyme might hydrolyse its substrates.
We earlier proposed the involvement of histidine and ty-
rosine residues in the catalytic mechanism of steroid sul-
phatase and its inhibition [25]. With the greater under-
standing of the generic active site sulphatase topology we
now feel it is crucial to reappraise these ideas and provide a
focus for further mechanistic work.
Eleven mammalian sulphatases have been identi¢ed: eight
in lysosomes, e.g. ASA and ASB, and three associated with
microsomal membranes, e.g. steroid sulphatase. These sul-
phatases are members of a highly conserved gene family
sharing extensive amino acid sequence homology [52,54], a
unique post-translational modi¢cation that is essential for
sulphate ester cleavage [52,55,56] as well as a high degree
of structural similarity [40,42]. In all different sulphatases
whose amino acid sequences have been resolved so far,
including steroid sulphatase, the active site amino acid
residues are conserved [40,52]. Presumably, enzyme spe-
ci¢city is derived from differential binding of the group
attached to sulphate in the various different types of sul-
phatase. The post-translational modi¢cation in functional
sulphatases involves the oxidation of a conserved cysteine
residue to L-CK-formylglycine (FGly) [52]. However, such
modi¢cation does not take place in sufferers of a rare dis-
order known as multiple sulphatase de¢ciency whose sul-
phatases are all severely impaired [40,52].
From the crystal structure analysis of ASB, the post-trans-
lational modi¢cation of cysteine occurs at residue 91 which
is replaced by a sulphate adduct of FGly [VCH(OH)^
OSO33 ] [40]. The amino acid residues that encompass
FGly91 and constitute the enzyme active site are Asp53,
Asp54, Pro93, Ser94, Arg95, Lys145, His147, His242,
Graphics 1. Molecular modelling of 667COUMATE (17, top) and
EMATE on SYBYL0 (Tripos Associate).
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Asp300 and Lys318 with Ca2 being identi¢ed as the co-
ordinating metal ion (Figure 6) [40]. For ASA, the pre-
dicted Cys69 is replaced by an aldehyde hydrate
[VCH(OH)2] which coordinates to a Mg2 ion via one
of its oxygen atoms [42]. The conserved residues lining
the active site pocket of ASA are Asp29, Asp30, *Lys123,
*Ser150, His125, *His229, Asp281, Asn282, *Lys302 (res-
idues marked with an asterisk are in close proximity to the
sulphate group of the substrate when it enters the active
site) [42]. It is anticipated that similar features are found in
the active site of steroid sulphatase in which a FGly resi-
due, coordinated by a metal ion, is embedded in a cluster
of conserved amino acid residues. An electrostatic potential
survey on ASA and ASB has shown a common feature that
the FGly residue is embedded within a positively charged
substrate binding pocket [40,42]. The putative interpreta-
tion for this observation is that the nitrogen-containing
amino acid residues lining the active site are protonated,
which through hydrogen bonding to the oxygen atoms of
the substrate might help stabilise the sulphate ester (Fig-
ure 6).
With the different resting forms of FGly observed in the
crystals of ASA and ASB, two different catalytic mecha-
nisms for desulphation of substrate are proposed [40,42].
For ASA [42], the reaction cycle is proposed to start with
an attack on the sulphur atom of the substrate by one of
the gem-diol oxygens, displacing the substrate alcohol as a
consequence (transesteri¢cation) (Figure 7, ASA). The re-
generation of free FGly from the sulphate adduct is sup-
posed to involve the elimination of the sulphate group
induced by the second, non-esteri¢ed hydroxyl group.
The free FGly so formed is then rehydrated back to an
aldehyde hydrate which is the resting form observed in
ASA. For ASB [40], the reaction sequence could be initi-
ated and proceed in a similar manner to that of ASA but
differs in that the reaction is arrested at the sulphate ad-
duct, which is apparently the resting form observed in the
crystal. However, it is also entirely possible that the reac-
tion sequence is initiated by one of the nucleophilic oxy-
gen atoms in the sulphate of the substrate attacking the
carbonyl group of FGly (Figure 7, ASB) to form a sulphate
ester and this was proposed by Bond et al. [40]. The dis-
placement of the substrate as an alcohol by water then
follows rendering the sulphate adduct of FGly.
In order to discriminate between the two hypothetical
mechanisms proposed above, the cysteine residue in the
precursor protein of ASA and ASB was replaced, using site-
directed mutagenesis, by a serine (VCH2^OH) which is
not oxidised to FGly in the cell lines used for the expres-
sion [41]. It was found that whilst the generated mutants
are able to cleave 35S-labelled substrate, only one catalytic
half-cycle was completed with the formation of a sulpho-
serine (VCH2^O35SO33 ). This sulphoserine-containing en-
zyme was found to be stable at pH 5 but the sulphate
group was hydrolysed slowly at alkaline pH. These char-
acteristics resemble those of alkaline phosphatase, whose
phosphoserine intermediate is also stable at pH 5, but is
hydrolysed at alkaline pH with no desulphation at acidic
pH. This apparent trapping of the serine mutants at the
sulphoserine intermediate is attributed to the absence of a
second gem-hydroxyl group. In wild-type ASA, the non-
esteri¢ed hydroxyl group is proposed to polarise the CL^
O bond of the sulphate adduct [VCLH(OH)^OSO33 ] and
hence assist its desulphation and the release of FGly.
These ¢ndings have thus presented a strong case for the
transesteri¢cation sequence described for ASA as the gen-
Figure 6. Sketch view of the catalytic site
of arylsulphatase B showing hydrogen-
bonded interactions (dashed lines) that
stabilise the sulphate ester. The seven-
coordinate metal ion is on the left. A salt
bridge interaction between Lys145 and the
O (carboxyl) atom of Asp53, which is not
coordinated to the metal ion, and a
number of charges and double bonds are
omitted from the ¢gure for clarity (adapted
from [40] with permission).
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eral mechanism through which sulphatases, including ste-
roid sulphatase, desulphate their substrates. If formation of
the sulphated FGly were initiated by addition of the sul-
phate ester to the oxo-group as proposed for ASB in Figure
7, no catalytic reaction should, in principle, be observed in
the serine mutant of ASB.
Although 667COUMATE has not been shown to be active
against other sulphatase enzymes apart from steroid sul-
phatase, based on the above insights into the mechanisms
for ASA- and ASB-catalysed sulphate hydrolysis (Figure 7)
and given that the essential residues for sulphatase activity
are conserved within the sulphatase family, several mech-
anisms for the inhibition of steroid sulphatase activity by
667COUMATE (or other related active site-directed sul-
phamates such as EMATE) are conceivable (Figs. 8^10).
The mechanisms we propose here thus replace the more
schematic ones [28,37,38] that were put forward previously,
and we consider all potential possibilities.
Involvement of FGly (Figure 8)
Since it has been proposed by Bond et al. that the resting
sulphated derivative of FGly observed in the crystals of
ASB could be in equilibrium with its free form [40], a
potential nucleophilic attack on the formyl group by the
lone-pair electrons of the N-atom of the sulphamate group
of 667COUMATE could be envisaged. The hemiaminal-
type intermediate (I, Figure 8) so formed could then be
hydrolysed to give 667COUMARIN and the sulphamoy-
lated enzyme II, which upon dehydration gives an imino
sulphamoylated enzyme IV (Figure 8, path A). Alterna-
tively, IV could be formed via hydrolysis of the ester III
after the dehydration of the hemiaminal intermediate I
(Figure 8, path B). We propose that II, III and IV and
possibly even I are ‘dead-end’ products and no regenera-
tion of FGly as in ASB (Figure 7, ASB) is therefore antici-
pated. The formation of an azomethine adduct similar to
III or IV is certainly not unprecedented for non-enzymatic
reaction. In the course of sulphamoylating a solution of
2-nitrophenol in dimethylformamide (DMF) after deproto-
nation with sodium hydride, an azomethine adduct of
2-nitrophenol-O-sulphamate and DMF, was isolated [28].
The mechanism proposed for its formation was similar to
the one described here in which the reaction is initiated by
an addition of the sulphamate to the carbonyl group of
DMF and progressed further by dehydration of the hemi-
aminal formed.
It cannot be ruled out that the nucleophilic attack on the
carbonyl group of FGly is initiated not by a neutral sul-
phamate but by its mono-anionic form (VOSO2NH3, Fig-
ure 8). Previous studies on various sulphamates have
shown that the N-proton is fairly acidic with a pKa value
in the range of 7^11, e.g. 10.53 for phenol sulphamate
(50% aqueous ethanol) [57], ca. 9.5 for EMATE (70%
aqueous MeOH) [58], 7.29 for 4-nitrophenol-O-sulphamate
(aqueous buffers) [59] and 7.05 for N-phenyl-4-nitrophe-
nol-O-sulphamate (50% aqueous acetonitrile) [60]. As an-
Figure 7. Proposed reaction scheme for sulphate ester cleavage by arylsulphatase A (ASA) and arylsulphatase B (ASB). FGly:
formylglycine.
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ticipated, the pKa of 667COUMATE in 50% aqueous
methanol as determined by potentiometric titration was
found to be 9.1 þ 0.1 (see Materials and methods). It is
known that in a mixed solvent system such as 50% aque-
ous methanol the alcohol weakens the strength of an acid
and the pKa value actually measured could therefore be
one or more units higher than that observed in water
[61]. This implies that at physiological pH a signi¢cant
proportion of the weak acid 667COUMATE could be in
its conjugate base form. The fact that the sulphamate N-
proton is fairly acidic also renders it susceptible to potential
proton abstraction by basic amino acid residues in the en-
zyme active site. Given that several lysine and histidine
residues are amongst the conserved amino acids found in
the active sites of sulphatases, it is also highly conceivable
that N-deprotonation of 667COUMATE takes place and
the resulting anionic species then acts as a nucleophile
attacking the FGly. The prospect of the involvement of
an anionic species of 667COUMATE and other related
sulphamate-based inhibitors in the inactivation of steroid
sulphatase is perhaps more ¢tting to what has been shown
in the crystal structures of ASA and ASB where the FGly
residue is located in a positively charged substrate binding
pocket coordinated by a bivalent metal ion. Since the sul-
phamoyl group is presumably acting as a sulphate surro-
gate, its anionic form (VOSO2NH3) should presumably
interact more favourably with the enzyme active site and
hence compete more effectively against E1S for binding
than the neutral form.
Involvement of the aldehyde hydrate (gem-diol residue)
(Figure 9)
Since an aldehyde hydrate was interpreted from the crystal
of ASA [42], it is possible that one of oxygens of the gem-
diol attacks the sulphur atom of the sulphamate group of
667COUMATE or other related irreversible inhibitors dis-
placing the starting phenol and forming a sulphamoylated
enzyme (I, Figure 9) as a result. This would be directly
analogous to the mechanism proposed for the desulphation
of substrate by ASA (see Figure 7, ASA). However, it is
dif¢cult to envisage convincingly that the sulphamoylated
enzyme I is potentially a dead-end product and unable to
proceed further since there is no apparent reason why the
sulphamate cannot be expelled by the other free hydroxyl
group of the gem-diol in a manner proposed for the regen-
eration of the aldehyde hydrate in ASA (see Figure 7,
ASA).
Random speci¢c or non-speci¢c sulphamoylation (Figure
10)
It is also possible that irreversibly inhibiting sulphamate
esters, including 667COUMATE, could inhibit steroid sul-
phatase in a more random manner by a speci¢c or non-
speci¢c sulphamoylation of amino acid residues in the ac-
tive site. Evidence for the involvement of two amino acid
residues in the inactivation process is provided by the bi-
phasic nature of inactivation exhibited by EMATE and
that two ionisable groups with pKa values of 7.2 and 9.8
are identi¢ed upon analysis of the pH dependence of en-
Figure 8. Proposed mechanism of steroid sulphatase inhibition by 667COUMATE involving the conserved formylglycine (FGly) residue in
the enzyme active site. Structures I, II, III and IV are proposed to be `dead-end' products.
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zyme activity and of enzyme inactivation by EMATE [25].
The ¢nding that rose bengal inhibited oestrone sulphatase
activity in a dose-dependent manner strongly suggested
that a histidine was involved in the catalytic mechanism
and also tyrosine was suspected since the pH dependence
of the inactivation process correlated with a residue of pKa
9.8 [25]. While the presence of two histidines in the en-
zyme active site has been con¢rmed, it is now known that
the conserved active site residues throughout the entire
family of sulphatases do not include tyrosine and so
some other residue of similar pKa must therefore be re-
sponsible. Since the pKa of the hydroxyl groups of the
gem-diol residue should be comparable to that of acetalde-
hyde hydrate at 13.6 [42], the most ¢tting residue in line
with our current knowledge is therefore lysine (e.g. Lys145
and Lys318 of ASB) which has a pKa value of V10 in
proteins [62]. We can thus reinterpret our previous ¢ndings
on the pH dependence of enzyme activity and of enzyme
inactivation by EMATE [25] in terms of histidine and
lysine residues. A recent report which examined active
site mutants of arylsulphatase A has con¢rmed the impor-
tance, inter alia, of the two lysine residues for sulphate
group binding and a histidine residue for catalysis [43].
Two mechanisms for such random speci¢c or non-speci¢c
sulphamoylation of active site amino acid residues are con-
ceivable. Firstly, via a direct nucleophilic attack at the
sulphur atom of 667COUMATE by an amino acid residue
in the enzyme active site (Figure 10, path A). This mech-
anism is analogous to Figure 9 except that the sulphamate
group of the inhibitor is attacked by a nucleophilic amino
acid residue other than the hydrated FGly. Secondly, and
more interestingly, via the formation of an electrophilic
sulphonylamine species involving an E1cB process on the
sulphamoyl group, possibly initiated by an enzyme-cata-
lysed N-proton abstraction and stimulated by H-bonding
to the bridging O-atom or coordination of the bridging O-
atom to a bivalent metal ion (Figure 10, path B). With what
is now known about the topology of the active sites of ASA
and ASB, the attacking nucleophile in mechanism A and
the N-proton abstracting amino acid residue in mechanism
B could well be either one of the conserved lysine or
histidine residues lining the active site of steroid sulpha-
tase. It is impossible to imagine that the reactive sulpho-
nylamine released as proposed in mechanism B could dif-
fuse out of the enzyme active site and be attacked by a
remote nucleophile. Given that lysine and histidine are
neighbouring amino acid residues of clear importance in
the catalytic mechanism, the products of inactivation would
most likely be sulphamidated enzyme intermediates (Fig-
ure 11A,B) which, we propose, could be dead-end prod-
ucts. From literature precedent and our experience with
sulphamides, e.g. oestrone 3-N-sulphamide [37] and some
coumarin sulphamides (unpublished observation), they are
Figure 10. Proposed random speci¢c or non-speci¢c
sulphamoylation by 667COUMATE of an essential amino acid
residue in the steroid sulphatase active site. Path A: via an attack
by a nucleophilic amino acid residue in the active site other than
the gem-diol residue (:Nu-H). Path B: via the generation of a
sulphonylamine species. No regeneration of the enzyme active
form from the sulphamoylated intermediate is expected. :B, a
proton-abstracting amino acid residue; X, a hydrogen bond-
donating amino acid residue or a coordinating metal ion. Dashed
line: hydrogen bonding.
Figure 9. Proposed mechanism of steroid sulphatase inhibition by
667COUMATE via a nucleophilic attack on the sulphamoyl group
by the hydrated form of formylglycine residue (aldehyde hydrate)
in the enzyme active site. Structure I is proposed to be a `dead-
end' product.
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inactive and stable entities and are therefore excellent can-
didates for a dead-end product of enzyme inactivation,
more so than the proposed gem-diol sulphamate of FGly
(I, Figure 9).
Since the isolation of a sulphamidated steroid sulphatase
after treatment of the enzyme with an irreversible inhibitor
like 667COUMATE has not yet been achieved, we felt it
would be pertinent to the above proposed mechanisms if a
transfer of sulphamoyl group from a coumarin sulphamate
to an amine mimicking lysine or histidine residue could be
demonstrated. Hence, experiments were performed in
which a solution of coumarin sulphamate in anhydrous
acetonitrile was stirred at room temperature with an excess
of either imidazole (cf. histidine) or 2,2-diphenylethyl-
amine (cf. lysine) in an atmosphere of nitrogen (see Mate-
rials and methods for details). With 2,2-diphenylethyl-
amine used as the base, the isolated product was found
to be the expected N-(2,2-diphenylethyl)sulphamide (25,
Ph2CHCH2NHSO2NH2). Similar aminolysis reactions of
various phenyl sulphamates by different types of amines
in either aqueous or non-aqueous organic media have also
demonstrated the formation of sulphamides as products
[57,60,63^65]. Kinetic studies for these reactions have gen-
erally supported an E1cB-like elimination mechanism in-
volving an sulphonylamine intermediate (RNNSO2)
[57,59,60,63^65]. When imidazole was used as the base,
no corresponding sulphamide was detected but instead a
salt (26) between imidazole and sulphamic acid was iso-
lated. This result thus indicates that under our reaction
conditions, upon an E1cB-like elimination of the sulpha-
moyl group, adventitious water in the solvent most likely
quenches the sulphonylamine formed to give sulphamic
acid which then forms a salt with imidazole. However, it
is entirely possible that in a more restricted environment
like that within the enzyme active site, where competing
water molecules might not be in close proximity, a nearby
histidine residue could well be the target of the electro-
philic sulphonylamine species to give a sulphamidated en-
zyme intermediate as the dead-end product.
All the above mechanisms proposed for the inactivation of
steroid sulphatase by an active site-directed sulphamate-
based inhibitor including 667COUMATE and EMATE
remain to be investigated and many questions have to be
answered before any of these mechanisms can be con-
¢rmed. Nonetheless, we now have good models for under-
standing how inhibition of sulphatase by sulphamate esters
may proceed, and these could be tested by experiment in
the future once puri¢ed soluble steroid sulphatase is avail-
able.
In conclusion, a highly potent, orally active, non-steroidal,
non-oestrogenic and irreversible steroid sulphatase inhibi-
tor has been developed. Based on current knowledge of
the conserved active site topology of sulphatases, several
mechanisms of action for a sulphamate-based active site-
directed steroid sulphatase inhibitor are proposed. With
667COUMATE now in pre-clinical development for Phase
I clinical trial, this will allow the biological and/or clinical
signi¢cance of steroid sulphatase inhibitors in the treat-
ment of postmenopausal women with HDBC to be fully
evaluated.
Signi¢cance
Breast cancer kills more women than any other forms of
cancer. In postmenopausal women, in whom breast cancer
most frequently occurs, about one-third of tumours are
hormone-dependent, and their growth and development
can be impeded when the tumour cells are deprived of
oestrogenic stimulation. Endocrine therapy has proven to
be effective in controlling hormone-dependent breast can-
cer (HDBC) and one important strategy is to reduce the
production of oestrogens in extraglandular tissues and also
within the tumour by inhibiting the conversion of andros-
tenedione to oestrone (E1) with aromatase inhibitors.
However, there is now convincing evidence that the dis-
appointing overall response rate observed in postmeno-
pausal women treated with the latest highly potent and
selective aromatase inhibitors is due to the lack of a con-
current inhibition of oestrone sulphatase and dehydro-
epiandrosterone (DHEA) sulphatase. The former enzyme
catalyses the hydrolysis of oestrone sulphate (E1S) to E1,
whereas the latter plays an important role in regulating the
production of oestrogenic steroids such as androstenediol.
Hence, steroid sulphatase inhibitors, when used alone or in
combination with an aromatase inhibitor, may enhance the
response of hormone-dependent breast tumours to this
type of endocrine therapy by reducing not only the forma-
tion of E1 from E1S but also the synthesis of oestrogenic
steroids from DHEA sulphate via DHEA.
Figure 11. Proposed irreversible inactivation of steroid sulphatase
via the formation of sulphamidated lysine (A) or histidine (B)
residue in the enzyme active site.
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In addition to its oncological role there is now evidence
that steroid sulphatase may regulate part of the immune
response and that inhibition of the enzyme can modulate
the immune response and have a bene¢cial effect in colla-
gen-induced rheumatoid arthritis. Recent studies have also
suggested that inhibition of steroid sulphatase might have
a role in the treatment of Alzheimer’s disease.
We have now developed a non-steroidal, non-oestrogenic,
orally active and highly potent active site-directed steroid
sulphatase inhibitor. This compound, 667COUMATE,
which is a tricyclic coumarin-based sulphamate, is now in
formal pre-clinical development for Phase I clinical trial
wherein the role of steroid sulphatase inhibitors in the
treatment of HDBC can be fully evaluated for the ¢rst
time. With our current knowledge of the structure^activity
relationship for steroid sulphatase inhibitors and also a bet-
ter understanding of how these inhibitors work, it is antici-
pated that even more powerful steroid sulphatase inhibi-
tors than 667COUMATE will be developed. The clinical
use of these compounds will not only supplement current
therapies in combating breast cancer but also allow the
potential use of steroid sulphatase inhibitors in other ther-
apeutic areas to be explored.
Materials and methods
Materials
All chemicals were either purchased from Aldrich Chemical Co. (Gilling-
ham, Dorset, UK) or Lancaster Synthesis (Morecambe, Lancashire, UK).
All organic solvents, of A.R. grade, were supplied by Fison plc (Lough-
borough, UK) and stored over 4 Aî molecular sieves. Anhydrous di-
methylformamide (DMF), used for all the sulphamoylation reactions,
was purchased from Aldrich and was stored under a positive pressure
of N2 after use. Sulphamoyl chloride was prepared by an adaptation of
the method of Appel and Berger [66] and was stored as a solution in
toluene as described by Woo et. al. [28,37]. An appropriate volume of
this solution was freshly concentrated in vacuo immediately before use.
E1S and E1 were purchased from Sigma Chemical Co. (Poole, UK).
[6,7-3H]E1S (speci¢c activity, 50 Ci/mmol) and [4-14C]E1 (speci¢c activ-
ity, 52 mCi/mmol) were purchased from New England Nuclear (Boston,
MA, USA).
Thin layer chromatography (TLC) was performed on pre-coated plates
(Merck TLC aluminium sheets silica gel 60 F254, Art. No. 5554). Prod-
uct(s) and starting material were detected by viewing under UV light (all
parent coumarins also give an intense purple £uorescence at 366 nm)
and/or treating with a methanolic solution of phosphomolybdic acid fol-
lowed by heating. Preparative TLC was performed on pre-coated plates
(Merck TLC silica gel 60 F254, 20U20 cm, layer thickness 2 mm, Art.
No. 5717) and bands were visualised under UV light. Flash column
chromatography was performed on silica gel (Sorbsil C60). IR spectra
were determined by a Perkin-Elmer 782 infrared spectrophotometer, and
peak positions are expressed in cm31. 1H and DEPT-edited 13C NMR
spectra of compounds were recorded with a Jeol JMN-GX270 and JMN-
GX400 NMR spectrometers, and chemical shifts are reported in parts
per million (ppm, N) relative to tetramethylsilane (TMS) as an internal
standard. FAB mass spectra were recorded at the Mass Spectrometry
Service Centre, University of Bath, using m-nitrobenzyl alcohol (NBA) as
the matrix. Elemental analyses were performed by the Microanalysis
Service, University of Bath. Melting points were determined using a
Reichert-Jung Thermo Galen Ko£er block and are uncorrected.
Biological studies were performed essentially as described previously
[24,25,67]. For more details, see legends of individual ¢gures or tables.
To examine whether the sodium salt of 6-oxo-3-sulphooxy-8,9,10,11-
tetrahydro-7H-cyclohepta-[c]][1]benzopyran (18, Scheme 2) could act
as a substrate for E1-STS, 100 Wg of the compound was incubated
for 1 h with placental microsomes in the absence or presence of EMATE
(10 WM). The product formed at the end of the incubation was extracted
into diethyl ether. After evaporation of solvent, the residue obtained was
examined by TLC using ether/methanol (2:1) as eluent. In this mobile
phase, the tricyclic sulphate, 18 and the parent 3-hydroxy-6-oxo-
8,9,10,11-tetrahydro-7H-cyclohepta-[c]][1]benzopyran (16, Scheme 2)
have Rf values of 0.6 and 0.86 respectively.
pKa determination of 667COUMATE
A 5 mM solution of 667COUMATE (17) in water/methanol (1:1) at room
temperature was prepared and its pH read (WPA Linton Cambridge UK,
CCMD625 pH meter). The titrant (50 mM KOH) was then added in equal
portions. The pH was recorded after each addition when equilibrium has
been reached (after stirring). The titration was completed within 10 min
after the ¢rst addition of titrant. The pKa was determined according to
the procedure of Albert and Serjeant [61].
Synthesis
4-Ethyl-7-hydroxycoumarin (3). Resorcinol (1.21 g, 11.0 mmol) was
dissolved in hot ethyl propionylacetate (1.52 g, 10.0 mmol). To this
stirred mixture at ice-water temperature was added dropwise a mixture
of tri£uoroacetic acid (1.70 ml, 22.0 mmol) and concentrated sulphuric
acid (2.2 ml, 22.0 mmol) at such a rate that the reaction temperature
was kept below 10³C (about 30 min). The reaction mixture was then
allowed to warm to room temperature and thereupon stirred for an addi-
tional 3 h before being quenched cautiously with ice-water. After stirring
the suspension that formed for 1 h, the bright yellow precipitate was
collected by suction ¢ltration, washed exhaustively with water and then
re-dissolved into acetone. The resulting solution was heated with acti-
vated charcoal, ¢ltered and evaporated to give a light orange residue
which was dried azeotropically with isopropyl alcohol. The crude product
that obtained was puri¢ed by recrystallisation from acetone/hexane (2:3)
to give 3 as creamy crystals (806 mg, 4.24 mmol, 42%); m.p. 175^
178³C [literature value [68] 177³C (ethanol)]; NH (400 MHz, DMSO-d6)
1.22 (3H, t, J = 7.3 Hz, CH3), 2.77 (2H, q, J = 7.3 Hz, CH2), 6.09 (1H, s,
C3-H), 6.71 (1H, d, JC6-H; C8-H = 2.4 Hz, C8-H), 6.80 (1H, dd,
JC8-H; C6-H = 2.4 Hz and JC5-H; C6-H = 8.4 Hz, C6-H), 7.64 (1H, d,
JC6-H; C5-H = 8.8 Hz, C5-H) and 10.53 (1H, s, exchanged with D2O,
OH); MS (FAB+) m/z (rel. intensity) 190.8 [100, (M+H)]; MS (FAB3)
m/z (rel. intensity) 342.8 [60, (M3H+NBA)3], 188.8 [100, (M3H)3].
Found: C, 69.4; H, 5.35; C11H10O3 requires C, 69.43; H, 5.30%.
4-Ethylcoumarin-7-O-sulphamate (4). To a stirred solution of 3
(400 mg, 1.96 mmol) in anhydrous DMF (5 ml) at 0³C under an atmos-
phere of N2 was added sodium hydride (60% dispersion, 78 mg, 1.96
mmol) followed by sulphamoyl chloride (3 eq.) after the evolution of
hydrogen had ceased. The reaction mixture was stirred under N2 at
room temperature overnight and then poured into water (150 ml). The
resulting mixture was extracted with ethyl acetate (150 ml) and the
organic portion separated was washed with brine (5U100 ml), dried
(MgSO4), ¢ltered and evaporated in vacuo at 40³C. The crude product
that obtained was recrystallised from ethyl acetate/hexane (1:1) to give
4 as white crystals (278 mg, 1.03 mmol, 49%); m.p. 168^169³C; NH (400
MHz, DMSO-d6) 1.25 (3H, t, J = 7.3 Hz, CH3), 2.85 (2H, q, J = 7.3 Hz,
CH2), 6.37 (1H, s, C3-H), 7.29 (1H, dd, JC8-H; C6-H = 2.4 Hz and
JC5-H; C6-H = 8.8 Hz, C6-H), 7.33 (1H, d, JC6-H; C8-H = 2.4 Hz, C8-H),
7.93 (1H, d, JC6-H; C5-H = 8.8 Hz, C5-H) and 8.24 (2H, s, exchanged
with D2O, OSO2NH2); MS (FAB+) m/z (rel. intensity) 270.1 [100,
(M+H)], 191.1 [10, (M+H3HNSO2)]; MS (FAB3) m/z (rel. intensity)
422.1 [15, (M+NBA)3], 268.0 [100, (M3H)3], 189.1 [35,
(M3H2NSO2)3]; HRMS (FAB+) m/z 270.04448 [(M+H)], calcd for
CHBIOL 22 2-10-00 Cyaan Magenta Geel Zwart
786 Chemistry & Biology 2000, Vol 7 No 10
C11H12NO5S 270.04362. Found: C, 48.9; H, 4.06; N, 5.04; C11H11NO5S
requires C, 49.06; H, 4.12; N, 5.20%.
7-Hydroxy-4-(n-propyl)coumarin (5). This was prepared from ethyl
butyrylacetate (1.61 g, 10.0 mmol) in a similar manner to the preparation
of 3. The crude product that obtained was puri¢ed by recrystallisation
from acetone/hexane (1:2) to give 5 as light yellow crystals (a total of
1.26 g, 6.17 mmol, 62%); m.p. 135^137³C [literature value [69] 130³C
(ethanol)]; NH (400 MHz, DMSO-d6) 0.97 (3H, t, J = 7.5 Hz, CH3), 1.63
(2H, sextet, J = 7.5 Hz, ^CH2CH2CH3), 2.71 (2H, t, J = 7.6 Hz,
^CH2CH2CH3), 6.08 (1H, s, C3-H), 6.71 (1H, d, J = 2.4 Hz, C8-H), 6.80
(1H, dd, J = 2.4 and 8.4 Hz, C6-H), 7.65 (1H, d, J = 8.5 Hz, C5-H) and
10.53 (1H, s, exchanged with D2O, OH); MS (FAB+) m/z (rel. intensity)
408.7 [15, (2M)], 204.8 [100, (M+H)]; MS (FAB3) m/z (rel. intensity)
406.8 [20, (2M3H)3], 356.8 [20, (M3H+NBA)3], 202.8 [100, (M3H)3].
Found: C, 70.5; H, 6.00; C12H12O3 requires C, 70.56; H, 5.93%.
4-(n-Propyl)coumarin-7-O-sulphamate (6). This was prepared
from 5 (400 mg, 1.96 mmol) in a similar manner to the preparation of 4.
The crude product that obtained was puri¢ed by recrystallisation from
ethyl acetate/hexane (1:1) to give 6 as white `cotton-like' crystals (242
mg, 854 Wmol, 44%); m.p. 174^178³C; TLC (chloroform/ethyl acetate,
2:1) Rf 0.32, cf. Rf 0.41 (5); NH (270 MHz, DMSO-d6) 0.99 (3H, t, J = 7.4
Hz, CH3), 1.66 (2H, sextet, J = 7.5 Hz, ^CH2CH2CH3), 2.80 (2H, t,
J = 7.5 Hz, ^CH2CH2CH3), 6.38 (1H, s, C3-H), 7.29 (1H, dd, J = 2.4
and 8.6 Hz, C6-H), 7.33 (1H, d, J = 2.4 Hz, C8-H), 7.95 (1H, d, J = 8.6
Hz, C5-H) and 8.25 (2H, s, exchanged with D2O, OSO2NH2); MS
(FAB+) m/z (rel. intensity) 284.1 [100, (M+H)], 205.2 [8,
(M+H3HNSO2)]; MS (FAB3) m/z (rel. intensity) 436.1 [15,
(M3H+NBA)3], 282.1 [100, (M3H)3], 203.1 [36, (M3H2NSO2)3];
HRMS (FAB+) m/z 284.05950 [(M+H)], calcd for C12H14NO5S
284.05927. Found: C, 50.8; H, 4.64; N, 4.81; C12H13NO5S requires C,
50.87; H, 4.63; N, 4.95%.
3-Ethyl-7-hydroxy-4-methylcoumarin (7). This was prepared from
ethyl 2-ethylacetoacetate (1.63 g, 10.0 mmol) in a similar manner to
the preparation of 3. The crude product that obtained was puri¢ed by
recrystallisation from isopropyl alcohol/hexane (3:5) to give 7 as white
crystals (a total of 1.24 g, 6.07 mmol, 61%); m.p. 201^203³C [literature
value [70] 196^197³C]; NH (400 MHz, DMSO-d6) 1.03 (3H, t, J = 7.5 Hz,
CH3), 2.36 (3H, s, C4-CH3), 2.54 (2H, q, J = 7.3 Hz, CH2), 6.68 (1H, d,
J = 2.4 Hz, C8-H), 6.79 (1H, dd, J = 2.4 and 8.4 Hz, C6-H), 7.60 (1H, d,
J = 8.8 Hz, C5-H) and 10.38 (1H, br s, exchanged with D2O, OH); MS
(FAB+) m/z (rel. intensity) 409.2 [10, (2M+H)], 205.2 [100, (M+H)];
MS (FAB3) m/z (rel. intensity) 407.2 [16, (2M3H)3], 357.2 [36,
(M+NBA)3], 203.2 [100, (M3H)3]; HRMS (FAB+) m/z 205.08669
[(M+H)], calcd for C12H13O3 205.08647. Found: C, 70.2; H, 5.93;
C12H12O3 requires C, 70.56; H, 5.93%.
3-Ethyl-4-methylcoumarin-7-O-sulphamate (8). This was pre-
pared from 7 (400 mg, 1.96 mmol) in a similar manner to the preparation
of 4. The crude product that obtained was puri¢ed by recrystallisation
from ethyl acetate/hexane (1:1) to give 8 as white crystals (204 mg, 720
Wmol, 37%); m.p. 179^181³C; NH (270 MHz, DMSO-d6) 1.06 (3H, t,
J = 7.5 Hz, CH3), 2.44 (3H, s, C4-CH3), 2.61 (2H, q, J = 7.5 Hz, CH2),
7.28 (2H, m, C6-H and C8-H), 7.89 (1H, d, J = 8.4 Hz, C5-H) and 8.21
(2H, br s, exchanged with D2O, OSO2NH2); MS (FAB+) m/z (rel. inten-
sity) 284.1 [100, (M+H)], 205.1 [14, (M+H3HNSO2)]; MS (FAB3) m/z
(rel. intensity) 436.1 [12, (M3H+NBA)3], 282.1 [100, (M3H)3], 203.1
[28, (M3H2NSO2)3]; HRMS (FAB+) m/z 284.05984 [(M+H)], calcd
for C12H14NO5S 284.05927. Found: C, 50.9; H, 4.67; N, 4.80;
C12H13NO5S requires C, 50.87; H, 4.63; N, 4.95%.
Ethyl 2-(n-propyl)acetoacetate (9). Keto ester 9 was synthesised
according to the method of Barbry et al. [71]. A mixture of potassium
carbonate (14 g, 0.10 mol), ethyl acetoacetate (4.3 g, 33 mmol),
1-iodopropane (5.7 g, 33.7 mmol), tetrabutylammonium chloride hydrate
(10 g), water (50 ml) and chloroform (50 ml) was stirred at room temper-
ature for 40 h. The aqueous layer was then separated, acidi¢ed with 5 M
hydrochloric acid and extracted with ether. The organic portions were
combined, concentrated and the residual tetrabutylammonium chloride
was precipitated by addition of ether. After ¢ltration, the ethereal ¢ltrate
was dried (MgSO4) and evaporated to give a yellow liquid which was
fractionated by distillation. The fraction which boiled at 93³C at V 15
mm Hg [literature value [72] 106^107³C, 22 mm Hg] was collected (2.13
g) and 1H NMR has indicated that this colourless liquid contained about
5% of ethyl acetoacetate and 95% of 9; NH (270 MHz, CDCl3) 0.93 (3H,
t, J = 7.3 Hz, CH3), 1.28 (5H, m, ^CH2CH2CH3 and CH3), 1.83 (2H, m,
^CH2CH2CH3), 2.23 (3H, s, CH3CO), 3.42 (1H, t, J = 7.3 Hz, ^CH)
and 4.20 (2H, q, J = 7.3 Hz, COOCH2CH3); MS (EI) m/z (rel. intensity)
172.1 (25, M), 143.1 [50, (M3Et)], 130.1 [28, (M+H3CH3CO)],
115.1 (23), 101.1 (40), 85.0 (20), 69.0 (30), 55.0 (30), 43.0 [100,
(CH3CO)]. This crude 9 was used for the next reaction without further
puri¢cation.
7-Hydroxy-4-methyl-3-(n-propyl)coumarin (10). This was pre-
pared from 9 (1.72 g) in a similar manner to the preparation of 3. The
yellow/brown crude product that obtained was fractionated by £ash chro-
matography (chloroform/acetone, 20:1 to 1:1 gradient). The product iso-
lated was further puri¢ed by recrystallisation from ethyl acetate/hexane
(2:3) to give 10 as creamy crystals (813 mg, 3.73 mmol, ca. 37%); m.p.
160^173³C [literature value [73] 171^173³C (aq. ethanol)]; NH (400 MHz,
DMSO-d6) 0.92 (3H, t, J = 7.3 Hz, CH3), 1.45 (2H, sextet, J = 7.5 Hz,
^CH2CH2CH3), 2.36 (3H, s, C4-CH3), 2.51 (2H, t, J = 7.7 Hz,
^CH2CH2CH3), 6.67 (1H, d, J = 2.4 Hz, C8-H), 6.79 (1H, dd, J = 2.4
and 8.4 Hz, C6-H), 7.60 (1H, d, J = 8.8 Hz, C5-H) and 10.38 (1H, br
s, exchanged with D2O, OH); MS (FAB+) m/z (rel. intensity) 437.2 [10,
(2M+H)], 219.2 [100, (M+H)]; MS (FAB3) m/z (rel. intensity) 435.2
[12, (2M3H)3], 371.1 [15, (M+NBA)3], 217.1 [100, (M3H)3]; HRMS
(FAB+) m/z 219.10300 [(M+H)], calcd for C13H15O3 219.10212. Found:
C, 71.7; H, 6.49; C13H14O3 requires C, 71.53; H, 6.47%.
4-Methyl-3-(n-propyl)coumarin-7-O-sulphamate (11). This was
prepared from 10 (300 mg, 1.38 mmol) in a similar manner to the prep-
aration of 4. The grey syrupy crude product that obtained was fraction-
ated by £ash chromatography (chloroform/ethyl acetate, 20:1 to 1:1
gradient). The product that isolated was further puri¢ed by recrystallisa-
tion from ethyl acetate/hexane (1:3) to give 11 as white crystals (137
mg, 461 Wmol, 34%); m.p. 139^142³C; NH (270 MHz, DMSO-d6) 0.93
(3H, t, J = 7.3 Hz, CH3), 1.48 (2H, m, ^CH2CH2CH3), 2.44 (3H, s, C4-
CH3), 2.58 (2H, t, J = 7.5 Hz, ^CH2CH2CH3), 7.27 (2H, m, C6-H and C8-
H), 7.89 (1H, d, J = 8.4 Hz, C5-H) and 8.21 (2H, s, exchanged with D2O,
OSO2NH2); MS (FAB+) m/z (rel. intensity) 298.1 [100, (M+H)]; MS
(FAB3) m/z (rel. intensity) 593.2 [25, (2M3H)3], 296.1 [100,
(M3H)3], 217.1 [45, (M3HNSO2)3]; HRMS (FAB+) m/z 298.07332
[(M+H)], calcd for C13H16NO5S 298.07492. Found: C, 52.4; H, 5.08;
N, 4.67; C13H15NO5S requires C, 52.51; H, 5.09; N, 4.71%.
7-Hydroxy-4-oxo-2,3-dihydro-1H-cyclopenta-[c]][1]benzopyran
(12). This was prepared from methyl 2-oxocyclopentane carboxylate
(1.47 g, 10.0 mmol) in a similar manner to the preparation of 3. The
crude product that obtained was puri¢ed by recrystallisation from isopro-
pyl alcohol/hexane (1:1) to give 12 as pale pink/white crystals (1.40 g,
6.92 mmol, 69%); m.p. 248^251³C [literature value [74] 243.5³C (aq.
ethanol)]; NH (270 MHz, DMSO-d6) 2.09 (2H, quintet, JV7.6 Hz, C2-
H2), 2.71 (2H, t, JV7.3 Hz, C3-H2), 3.02 (2H, t, JV7.7 Hz, C1-H2), 6.74
(1H, d, JC8-H; C6-H = 2.2 Hz, C6-H), 6.79 (1H, dd, JC6-H; C8-H = 2.2 Hz and
JC9-H; C8-HV8.4 Hz, C8-H), 7.43 (1H, d, JC8-H; C9-H = 8.4 Hz, C9-H) and
10.43 (1H, br s, exchanged with D2O, OH); MS (FAB+) m/z (rel. inten-
sity) 203.2 [100, (M+H)]; MS (FAB3) m/z (rel. intensity) 355.2 [36,
(M+NBA)3], 201.1 [100, (M3H)3]. Found: C, 71.0; H, 4.90; C12H10O3
requires C, 71.26; H, 4.99%.
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4-Oxo-2,3-dihydro-1H-cyclopenta-[c]][1]benzopyran-7-O-sulpha-
mate (13). This was prepared from 12 (500 mg, 2.47 mmol) in a
similar manner to the preparation of 4. The crude product that obtained
was puri¢ed by recrystallisation from acetone/hexane (3:5) to give 13 as
white crystals (403 mg, 1.43 mmol, 58%); m.p. 193^195³C; NH (400
MHz, acetone-d6) 2.22 (2H, quintet, JV7.6 Hz, C2-H2), 2.84 (2H, m,
C3-H2), 3.15 (2H, m, C1-H2), 7.29 (1H, dd, JC6-H; C8-HV2.2 Hz and
JC9-H; C8-H = 8.7 Hz, C8-H), 7.33 (1H, d, JC8-H; C6-H = 2.1 Hz, C6-H),
7.35 (2H, br s, exchanged with D2O, OSO2NH2) and 7.67 (1H, d,
JC8-H; C9-H = 8.2 Hz, C9-H); MS (FAB+) m/z (rel. intensity) 282.0
[100, (M+H)], 202.1 [10, (M3HNSO2)]; MS (FAB3) m/z (rel. inten-
sity) 434.1 [22, (M+NBA)3], 280.1 [100, (M3H)3], 201.1 [26,
(M3H2NSO2)3]; HRMS (FAB+) m/z 282.04493 [(M+H)], calcd for
C12H12NO5S 282.04362. Found: C, 51.3; H, 3.84; N, 4.90; C12H11NO5S
requires C, 51.24; H, 3.94; 4.98%.
3-Hydroxy-6-oxo-7,8,9,10-tetrahydro-dibenzo[b,d]pyran
(14). This was prepared from ethyl 2-cyclohexanone carboxylate (1.79
g, 10.0 mmol) in a similar manner to the preparation of 3. The crude
product that obtained was puri¢ed by recrystallisation from isopropyl
alcohol/hexane (3:2) to give 14 as creamy crystals (1.45 g, 6.71
mmol, 67%); m.p. 200^202³C [literature value [75] 203^204³C (aq. etha-
nol)]; NH (270 MHz, DMSO-d6) 1.74 (4H, m, C8-H2 and C9-H2), 2.38
(2H, m, C7-H2), 2.74 (2H, m, C10-H2*), 6.69 (1H, d, JC2-H; C4-H = 2.2 Hz,
C4-H), 6.78 (1H, dd, JC4-H; C2-H = 2.4 Hz and JC1-H; C2-H = 8.6 Hz, C2-H),
7.53 (1H, d, JC2-H; C1-H = 8.4 Hz, C1-H*) and 10.34 (1H, s, exchanged
with D2O, OH); NC (100.4 MHz, DMSO-d6) 20.77 (t), 21.16 (t), 23.39 (t),
24.51 (t), 101.83 (d), 111.87 (s), 112.56 (d), 118.34 (s), 124.93 (d),
147.58 (s), 152.94 (s), 159.76 (s) and 160.90 (s); MS (FAB+) m/z (rel.
intensity) 217.2 [100, (M+H)]; MS (FAB3) m/z (rel. intensity) 369.2 [30,
(M+NBA)3], 215.1 [100, (M3H)3]. Found: C, 72.0; H, 5.60; C13H12O3
requires C,72.21; H, 5.59%. *An NOE interaction was observed between
these protons.
6-Oxo-7,8,9,10-tetrahydro-dibenzo[b,d]pyran-3-O-sulphamate
(15). This was prepared from 14 (300 mg, 1.39 mmol) in a similar
manner to the preparation of 4. The crude product that obtained was
puri¢ed by recrystallisation from acetone/hexane (1:2) to give 15 as
white crystals (204 mg, 691 Wmol, 50%); m.p. 184.5^186.5³C; NH (270
MHz, acetone-d6) 1.84 (4H, m, C8-H2 and C9-H2), 2.50 (2H, m, C7-H2),
2.85 (2H, m, C10-H2), 7.3 (4H, m, 2H exchanged with D2O, C2-H, C4-H
and OSO2NH2) and 7.78 (1H, d, JC2-H; C1-HV8 Hz, C1-H); MS (FAB+)
m/z (rel. intensity) 296.3 [100, (M+H)], 217.2 [13, (M+H3HNSO2)];
MS (FAB3) m/z (rel. intensity) 448.1 [14, (M+NBA)3], 294.1 [100,
(M3H)3], 215.1 [28, (M3H2NSO2)3]; HRMS (FAB+) m/z 296.05921
[(M+H)], calcd for C13H14NO5S 296.05927. Found: C, 53.0; H, 4.50;
N, 4.60; C13H13NO5S requires C, 52.87; H, 4.44; N, 4.75%.
3-Hydroxy-6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c]][1]ben-
zopyran (16). This was prepared from methyl 2-oxocycloheptane car-
boxylate (1.72 g, 10.0 mmol) in a similar manner to the preparation of 3.
The crude product that obtained was puri¢ed by recrystallisation from
ethyl acetate/hexane (7:4) to give 16 as creamy crystals (1.47 g, 6.38
mmol, 64%); m.p. 189^190³C [literature value [76] 188.5^189.5³C (etha-
nol)]; NH (400 MHz, DMSO-d6) 1.49 (2H, m), 1.58 (2H, m), 1.83 (2H, m),
2.76 (2H, m, C7-H2), 2.93 (2H, m, C11-H2), 6.70 (1H, d, J = 2.4 Hz,
C4-H), 6.78 (1H, dd, J = 2.4 and 8.7 Hz, C2-H), 7.71 (1H, d, J = 8.8
Hz, C1-H) and 10.41 (1H, br s, exchanged with D2O, OH); MS
(FAB+) m/z (rel. intensity) 461.2 [13, (2M+H)], 231.1 [100, (M+H)];
MS (FAB3) m/z (rel. intensity) 383.3 [25, (M+NBA)3], 229.2 [100,
(M3H)3]. Found: C, 73.1; H, 6.16; C14H14O3 requires C, 73.01; H,
6.13%.
6-Oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c]][1]benzopyran-3-
O-sulphamate (17). This was prepared from 16 (400 mg, 1.74 mmol)
in a similar manner to the preparation of 4. The crude product that
obtained was fractionated by £ash chromatography (chloroform/ethyl
acetate, 8:1 to 2:1, gradient) and the product that isolated was further
puri¢ed by recrystallisation from ethyl acetate/hexane (3:5) to give 17 as
white crystals (310 mg, 1.00 mmol, 58%); m.p. 169^171³C; TLC (chloro-
form/ethyl acetate, 4:1) Rf 0.33, cf. Rf 0.52 (18); IR (KBr) 3310, 3060,
2930, 2860, 1690, 1610, 1390, 1190; NH (270 MHz, acetone-d6) 1.61
(2H, m), 1.70 (2H, m), 1.94 (2H, m), 2.90 (2H, m, C7-H2), 3.07 (2H, m,
C11-H2), 7.29 (2H, m, C2-H and C4-H), 7.36 (2H, br s, exchanged with
D2O, OSO2NH2) and 7.95 (1H, d, JV9 Hz, C1-H); MS (FAB+) m/z (rel.
intensity) 310.1 [100, (M+H)], 230.1 [10, (M3HNSO2)]; MS (FAB3)
m/z (rel. intensity) 462.3 [15, (M+NBA)3], 308.2 [100, (M3H)3], 229.2
[36, (M3H2NSO2)3]; HRMS (FAB+) m/z 310.07529 [(M+H)], calcd for
C14H16NO5S 310.07492. Found: C, 54.35; H, 4.96; N, 4.53;
C14H15NO5S requires C, 54.36; H, 4.89; N, 4.53%.
6-Oxo-3-sulphooxy-8,9,10,11-tetrahydro-7H-cyclohepta-[c]][1]-
benzopyran (18). To a stirred solution of 16 (100 mg, 434 Wmol) in
sodium hydroxide (V1 M, 1.5 ml) at room temperature was added
sulphur trioxide^trimethylamine complex (126 mg, 868 Wmol). After
being stirred for 3 days, the reaction mixture was fractionated by £ash
chromatography (ether; then ether/methanol, 4:1 to 1:1, gradient) to give
18 as dull white residue (110 mg); TLC (ether/methanol, 2:1) Rf 0.6, cf.
Rf 0.86 (16 in V1 M NaOH); NH (400 MHz, DMSO-d6) 1.50 (2H, m),
1.60 (2H, m), 1.84 (2H, m), 2.79 (2H, m, C7-H2), 2.98 (2H, m, C11-H2),
7.15 (1H, dd, J = 2.3 and 8.7 Hz, C2-H), 7.18 (1H, d, J = 2.1 Hz, C4-H)
and 7.81 (1H, d, J = 8.8 Hz, C1-H); MS (FAB3) m/z (rel. intensity) 641.1
[18, (2M3Na)3], 485.1 [16, (M3H+NBA)3], 309.1 [100, (M3Na)3],
229.1 [26, (M3Na3SO3)3]; HRMS (FAB3) m/z 309.04310
[(M3Na)], calcd for C14H13O6S 309.04329.
3-Hydroxy-6-oxo-7,8,9,10,11,12-hexahydro-cycloocta-[c]][1]ben-
zopyran (19). This was prepared from methyl 2-oxocyclooctane car-
boxylate (1.02 g, 5.0 mmol) and resorcinol (610 mg, 5.5 mmol) in a
similar manner to the preparation of 3. After quenching the reaction
mixture with ice-water, the crude product was extracted into ethyl ace-
tate (150 ml). The organic portion which separated was then further
washed with brine (5U100 ml), dried (MgSO4), ¢ltered and evaporated.
The orange liquid/solid obtained was then fractionated by £ash chroma-
tography (ethyl acetate/hexane, 1:4 to 2:1 gradient) and 19 that isolated
(405 mg, 1.66 mmol, 33%) was recrystallised from ethyl acetate/hexane
(5:2) to give ¢ne white crystals (256 mg); TLC (ethyl acetate/hexane,
1:1) Rf 0.42, cf. Rfs 0.7 (keto ester); m.p. 232^234³C; NH (400 MHz,
DMSO-d6) 1.38 (2H, m), 1.49 (2H, m), 1.60 (2H, m), 1.74 (2H, m), 2.71
(2H, t, JV5.6 Hz, C7-H2), 2.99 (2H, t, JV6.3 Hz, C12-H2), 6.72 (1H, d,
J = 2.4 Hz, C4-H), 6.81 (1H, dd, J = 2.3 and 8.7 Hz, C2-H), 7.66 (1H, d,
J = 8.8 Hz, C1-H) and 10.42 (1H, br s, exchanged with D2O, OH); MS
(FAB+) m/z (rel. intensity) 245.1 [100, (M+H)]; MS (FAB3) m/z (rel.
intensity) 397.3 [30, (M+NBA)3], 243.2 [100, (M3H)3]. Found: C, 73.6;
H, 6.67; C15H16O3 requires C, 73.74; H, 6.61%. About 500 mg of the
starting keto ester was retrieved.
6-Oxo-7,8,9,10,11,12-hexahydro-cycloocta-[c]][1]benzopyran-3-
O-sulphamate (20). This was prepared from 19 (421 mg, 1.72 mmol)
in a similar manner to the preparation of 4. The crude product that
obtained was fractionated by £ash chromatography (chloroform/ethyl
acetate, 8:1 to 4:1, gradient) and the product that isolated was further
puri¢ed by recrystallisation from ethyl acetate/hexane (1:2) to give 20 as
white crystals (305 mg, 943 Wmol, 55%); m.p. 174^175.5³C; NH (270
MHz, acetone-d6) 1.47 (2H, m), 1.55 (2H, m), 1.68 (2H, m), 1.86 (2H,
m), 2.84 (2H, t, JV6.5 Hz, C7-H2), 3.10 (2H, t, JV6.5 Hz, C12-H2),
7.28 (2H, m, C2-H and C4-H), 7.37 (2H, br s, exchanged with D2O,
OSO2NH2) and 7.93 (1H, d, JV9 Hz, C1-H); MS (FAB+) m/z (rel.
intensity) 324.1 [100, (M+H)], 244.1 [13, (M3HNSO2)]; MS (FAB3)
m/z (rel. intensity) 476.3 [64, (M+NBA)3], 323.2 (58, M3), 243.3 [100,
(M3H2NSO2)3]; HRMS (FAB+) m/z 324.08971 [(M+H)], calcd for
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C15H18NO5S 324.09057. Found: C, 55.8; H, 5.39; N, 4.39; C15H17NO5S
requires C, 55.71; H, 5.30; N, 4.33%.
3-Hydroxy-6-oxo-6,7,8,9,10,11-hexahydrodibenz[b,d]oxepin
(21). This was prepared from ethyl (2-oxocyclohexyl)acetate (1.90 g,
10.0 mmol) in a similar manner to the preparation of 3. The brown crude
product that obtained was fractionated by £ash chromatography to give
21 as a creamy residue (439 mg, 1.91 mmol, 19%); TLC (chloroform/
ethyl acetate, 4:1) Rf 0.46, cf. 0.19 (resorcinol); MS (FAB+) m/z (rel.
intensity) 461.3 [12, (2M+H)], 230.1 (100, M); MS (FAB3) m/z (rel.
intensity) 383.2 [40, (M3H+NBA)3], 229.2 [100, (M3H)3]; HRMS
(FAB+) m/z 230.09451 (M), calcd for C14H14O3 230.09429. The 1H
NMR spectrum of 21 in CDCl3 agrees with that reported by Hua et al.
[77]. The phenolic 21 was sulphamoylated without further puri¢cation.
6-Oxo-6,7,8,9,10,11-hexahydrodibenz[b,d]oxepin-3-O-sulpha-
mate (22). This was prepared from 21 (389 mg, 1.69 mmol) in a
similar manner to the preparation of 4. The brown syrup that obtained
was fractionated by £ash chromatography (chloroform/ethyl acetate, 8:1
to 2:1, gradient) and the product that isolated was further puri¢ed by
recrystallisation from ethyl acetate/hexane (1:1) to give 22 as white
crystals (186 mg, 601 Wmol, 36%); m.p. 183^186³C; NH (400 MHz,
acetone-d6) 1.76 (4H, m, C9-H2 and C10-H2), 2.35 (2H, br s, CH2),
2.53 (2H, v br s, CH2), 2.85 (2H, s, C7-H2), 7.17 (1H, d, J = 2.4 Hz,
C4-H), 7.24 (3H, reduced to 1H upon exchange with D2O, dd, J = 2.6
and 8.7 Hz, C2-H and OSO2NH2) and 7.65 (1H, d, J = 8.8 Hz, C1-H).
Found: C, 54.5; H, 4.97; N, 4.54; C14H15NO5S requires C, 54.36; H,
4.89; N, 4.53%.
N-(2,2-Diphenylethyl)sulphamide (25). To a stirred solution of 4-(n-
propyl)coumarin-7-O-sulphamate (6) (100 mg, 353 Wmol) in anhydrous
acetonitrile under nitrogen at room temperature was added 2,2-diphe-
nylethylamine (4 eq.) and the progress of the reaction was monitored by
TLC (products were detected by treating with a methanolic solution of
phosphomolybdic acid followed by heating). The disappearance of 6
was completed after 48 h with the formation of 7-hydroxycoumarin-4-
(n-propyl)coumarin (5) and sulphamide 25. Upon evaporation of the
reaction mixture in vacuo, the light yellow syrup that resulted in ethyl
acetate (50 ml) was washed with dilute hydrochloric acid (2U30 ml) and
then water to neutral. The organic layer was left to evaporate in the
fume cupboard and the creamy residue that obtained was fractionated
on preparative TLC eluted with chloroform/acetone (4:1) to give sulpha-
mide 25 (Rf 0.41, cf. Rf 0.56 for 5) as creamy residue (52 mg, 188 Wmol,
53%); IR (KBr) 3360, 3260, 1430, 1350, 1160; NH (270 MHz, DMSO-d6)
3.50 (2H, t, JW7 Hz, CH2NH), 4.22 (1H, t, JW7^8 Hz, CH), 6.47 (1H, t,
JW5 Hz, exchanged with D2O, NH), 6.57 (2H, s, exchanged with D2O,
SO2NH2) and 7.2^7.4 (10H, m, Ar); MS (FAB+) m/z (rel. intensity)
277.1 [100, (M+H)], 181.1 [97, (M+H3H2NSO2NH2)], 97.1 [52,
(H3NSO2NH2)]; MS (FAB3) m/z (rel. intensity) 429.2 [65,
(M+NBA)3], 275.2 [100, (M3H)3], 95.0 [38, HNSO2NH2)3]; HRMS
(FAB+) m/z 277.10133 [(M+H)], calcd for C14H17N2O2S 277.10108.
Sulphamic acid and imidazole salt (26). The reaction was carried
out in a similar manner to 25 except that imidazole (4 eq.) was used.
White precipitate was detected after the reaction mixture was stirred for
17 h and the disappearance of coumarin sulphamate 6 was completed
after 4 days. The white precipitate formed was ¢ltered, washed several
times with fresh acetonitrile and air-dried to give salt 26 as white residue
(43 mg, 261 Wmol, 70%); m.p. 152^154³C; IR (KBr) 3300, 3240, 3150,
3000, 2860, 1590; NH (400 MHz, DMSO-d6) 7.40 (2H, s) and 8.45 (1H,
s); MS (FAB+) m/z (rel. intensity) 375.2 [18, (imidazole+H+2NBA)],
222.1 [100, (imidazole+H+NBA)], 69.0 [16, (imidazole+H)]; MS
(FAB3) m/z (rel. intensity) 402.0 [35, (H2NSO2O+2NBA)3], 249.0
[100, (H2NSO2O+NBA)3], 95.9 [65, H2NSO2O3]. Found: C, 22.0; H,
4.29; N, 25.2; C3H7N3O3S requires C, 21.82; H, 4.27; N, 25.44%. The
melting point, the IR and MS spectra of 26 were comparable to those of
the white solid (m.p. 148^154³C) precipitated upon addition of a solution
of sulphamic acid in DMF dropwise to a solution of imidazole in aceto-
nitrile.
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